久久久久人妻精品一区5555,国产精品有码在线观看

TMC353121

NMR下載 COA and HPLC MSDS下載
names：
TMC353121
CAS號：
857066-90-1
MDL Number： MFCD18633233
MF(分子式)： C32H42N6O3 MW(分子量)： 558.71
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11249932 Brand:BIOFOUNT

TMC353121(857066-90-1)是有效的RSV融合抑制劑。TMC353121的活性概況與JNJ-2408068的概況相同。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000869-10mg	10mg	98%	￥ 2636.00	￥ 2636.00		2-3天	- +	￥ 0.00
YZM000869-5mg	5mg	98%	￥ 1360.00	￥ 1360.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	TMC353121(857066-90-1);TMC-353121;TMC 353121
英文別名	TMC353121,857066-90-1
CAS號	857066-90-1
Inchi	InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)
InchiKey	DKORMNNYNRPTBJ-UHFFFAOYSA-N
分子式 Formula	C32H42N6O3
分子量 Molecular Weight	558.71
溶解度Solubility	生物體外In Vitro:DMSO溶解度50 mg/mL(89.49 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性狀	粉紅色到紅色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

TMC353121(857066-90-1)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

TMC353121(857066-90-1) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:TMC353121(857066-90-1),TMC353121試劑,TMC353121抑制劑,TMC353121的作用,TMC353121的純度,TMC353121的合成,TMC353121的含量,TMC353121的生產(chǎn),TMC353121的使用,TMC353121的MSDS,TMC353121的效果,TMC353121的外觀

產(chǎn)品說明	TMC353121(857066-90-1) 是一種有效的呼吸道合胞病毒 (RSV) 融合的抑制劑，pEC50是 9.9
Introduction	TMC353121(857066-90-1) is a potent respiratory syncytial virus (RSV) fusion inhibitor withpEC50of 9.9.
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus

Respiratory Syncytial Virus Disease: Prevention and Treatment(Challenges and Opportunities for Respiratory Syncytial Virus Vaccines,2013)

Evaluation of Antiviral Efficacy Against Human Respiratory Syncytial Virus Using Cotton Rat and Mouse Models(Antiviral Methods and Protocols,2013)

Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins
Abstract:The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of infection. G targets the ciliated cells of the airways, and F causes the virion membrane to fuse with the target cell membrane. The F protein is the major target for antiviral drug development, and both G and F glycoproteins are the antigens targeted by neutralizing antibodies induced by infection. In this chapter, we review the structure and function of the RSV surface glycoproteins, including recent X-ray crystallographic data of the F glycoprotein in its pre- and postfusion conformations, and discuss how this information informs antigen selection and vaccine development.

Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.Bonfanti JF;Roymans D Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
Abstract:Human respiratory syncytial virus (hRSV) is a significant cause of respiratory illness in at-risk pediatric patients, immunocompromised adults and the elderly. No vaccine is currently available for the virus and treatment options are limited to the prophylactic treatment of at-risk infants with the mAb palivizumab (Synagis) and to therapeutic intervention with the nucleoside analog ribavirin (Rebetol). The clinical use of these agents is limited and a need exists for more effective treatment for the at-risk population. The merging of viral and cellular membranes is a crucial event in the hRSV life cycle that enables the virus to enter a host cell. The multistep fusion process is facilitated by the substantial refolding of a trimeric class I fusion protein (F protein), which is the main target of fusion inhibitors. Several small-molecule fusion inhibitors have been discovered, of which some have progressed significantly in the drug development process. BTA-9881 (Biota Holdings Ltd/MedImmune) and TMC-353121 (Johnson & Johnson) are the most advanced of this drug class. In addition, progress has been made in the development of next-generation antibodies such as motavizumab (Numax; MedImmune).

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開